54646-75-2

Usage

Uses

Used in Organic Synthesis:
1-BROMO-8-PHENYLOCTANE is used as a reagent and intermediate in organic synthesis for its ability to facilitate the creation of complex organic molecules. Its bromine atom and phenyl group contribute to its reactivity and versatility in chemical reactions.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 1-BROMO-8-PHENYLOCTANE is used as a key intermediate in the synthesis of various drugs. Its unique structure allows for the development of new pharmaceutical compounds with specific therapeutic properties.
Used in Agrochemicals:
1-BROMO-8-PHENYLOCTANE is utilized as a precursor in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals that enhance crop protection and yield.
Used in Specialty Chemicals:
1-BROMO-8-PHENYLOCTANE is also employed in the manufacture of specialty chemicals, where its distinctive properties are leveraged to create high-value products for niche applications.
Used as a Solvent in Manufacturing Processes:
Due to its solubility properties, 1-BROMO-8-PHENYLOCTANE may be used as a solvent in certain manufacturing processes, particularly where its unique solvency characteristics are required for specific tasks or reactions.

InChI:InChI=1/C14H21Br/c15-13-9-4-2-1-3-6-10-14-11-7-5-8-12-14/h5,7-8,11-12H,1-4,6,9-10,13H2

Upstream product

• 10472-97-6 8-phenyloctan-1-ol 
• 4549-32-0 1,8-dibromooctane 
• 591-51-5 phenyllithium 
• 142-68-7 TETRAHYDROPYRANE 
• 637-59-2 1-Bromo-3-phenylpropane 
• 100863-10-3 trans-8-Phenyl-octen-⁽⁴⁾-ol-⁽¹⁾ 
• 111-87-5 octanol 
• 558-13-4 carbon tetrabromide 
• 4549-31-9 1,7-dibromoheptane 
• 1589-82-8 phenylmagnesium bromide 
• 5631-95-8 2,3-dichlorotetrahydro-2H-pyran 
• 65921-65-5 5-iodopentyl acetate 
• 101277-51-4 6-oxo-8-phenyl-octanoic acid ethyl ester 
• 100-58-3 phenylmagnesium bromide 

Downstream Products

• 102373-00-2 1-Phenyl-8-(4-nitro-2-methoxy-phenoxy)-octan 
• 96964-42-0 2-[2-(8-phenyloctyl)phenyl]-4,4-dimethyloxazoline 
• 61440-33-3 ethyl p-[(8-phenyloctyl)amino]benzoate 
• 1026866-56-7 6-Methyl-3-(8-phenyl-octyloxy)-pyridine-2-carbaldehyde 
• 134520-01-7 N,N-dimethyl-8-phenyloctylamine 
• 96964-45-3 2-(8-phenyloctyl) benzaldehyde 
• 96964-40-8 SKF 102922 
• 15382-78-2 1-Phenyl-8-<4-amino-2-methoxy-phenoxy>-octan 
• 1333230-01-5 8-phenyloctanethiol 

Relevant academic research and scientific papers

Air-Stable PdI Dimer Enabled Remote Functionalization: Access to Fluorinated 1,1-Diaryl Alkanes with Unprecedented Speed

While remote functionalization via chain walking has the potential to enable access to molecules via novel disconnections, such processes require relatively long reaction times and can be in need of elevated temperatures. This work features a remote arylation in less than 10 min reaction time at room temperature over a distance of up to 11 carbons. The unprecedented speed is enabled by the air-stable PdI dimer [Pd(μ-I)(PCy2tBu)]2, which in contrast to its PtBu3 counterpart does not trigger direct coupling at the initiation site, but regioconvergent and chemoselective remote functionalization to yield valuable fluorinated 1,1-diaryl alkanes. Our combined experimental and computational studies rationalize the origins of switchability, which are primarily due to differences in dispersion interactions.

Bent-core mesogens with an aromatic unit at the terminal position

Bent-core liquid crystals with a naphthalene central unit and an aromatic ring at the terminal position of molecular tails were synthesised with the aim of enhancing nanosegregation. It was found that the length of the spacer between the rigid core and the terminal aromatic moiety had a profound influence on the liquid crystal polymorphism. The homologues with short spacers exhibited nematic and columnar phases, whereas the homologue with long spacers exhibited a tilted lamellar phase with a liquid-like in-plane order, indicating an unusual morphology of the densely packed toroidal objects. The morphology can be changed to twisted ribbons by small additives adsorbed on the membrane surface. This is the first example of twisted ribbons constructed by a lamellar system with no long-range in-plane order.

Effect of composition on the catalytic properties of mixed-ligand-coated gold nanoparticles

Striped catalysts: The effect of composition and structure on the catalytic efficiency of gold nanoparticles protected by a monolayer composed of two types of ligands differing in length (see picture) is reported. By diluting catalytically active ligand molecules with simple catalytically inactive molecules the catalytic efficiency of the particles is enhanced.

Probing structure/affinity relationships for the Plasmodium falciparum hexose transporter with glucose derivatives

A series of 3-O-substituted glucose derivatives was prepared with alkyl, alkenyl, aromatic and ferrocenic substituents; to vary lipophilicity and hydrogen bonding ethylenedioxy and perfluorinated fragments were also introduced. Apparent affinities for the Plasmodium falciparum hexose transporter (PfHT) were determined after heterologous expression in Xenopus oocytes, with highest affinities for compounds with C8-C13 lipophilic chains. As no derivatives show significant affinity for the mammalian glucose transporter (GLUT1), these structure/affinity assays contribute to design of potent PfHT inhibitors and eventual development of antimalarials.

Dangling arms: A tetrahedral supramolecular host with partially encapsulated guests

A protruding tail: A guest composed of a cationic sandwich complex, an alkyl chain, and a sulfonate anionic group is partially incorporated within a host [Ga4L6]12- cluster (see scheme). The cationic head group is quickly incorporated into the cavity of the host, while the sulfonate unit at the other end of the chain is not, as the alkyl sulfonate tail protrudes through an opening in a triangular face of the tetrahedral cluster. (Figure Presented).

2,2-Dichloroalkanecarboxylic acids, processes for their production and pharmaceutical agents containing these

Pharmaceutical agents for treating diabetus mellitus which contain a compound of formula I STR1 as the active substance, in which A, B, A' and W have the meanings stated in the claims, new compounds of formula I as well as processes for their production.

Zwitterionic sulfobetaine inhibitors of squalene synthase

A substantial number of sulfobetaines (e.g., 10) have been synthesized and evaluated as inhibitors of squalene synthase (SS) on the basis of the idea that their zwitterionic structure would have properties conducive both to binding in the active site and to passage through cell membranes. When the simple sulfobetaine moiety is incorporated into compounds containing hydrophobic portions like those in farnesyl diphosphate (1) or presqualene diphosphate (2), inhibition of SS in a rat liver microsomal assay was indeed observed. For example, farnesylated sulfobetaine 10 has IC50 = 10 μM and aromatic derivative 35 has IC50 = 2 μM for SS inhibition. A wide variety of structural modifications, exemplified by compounds 43, 52, 76, 85, 91, 99, 111, and 115, was investigated. Unfortunately, no inhibitors in the submicromolar range were discovered, and exploration of a different type of zwitterion seems necessary if this appealing approach to inhibition of SS is going to provide a potential antihypercholesterolemic agent.

ω-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents

In screening experiments certain ω-substituted alkyl carboxylic acids were found to produce an increase in insulin-stimulated 14C-acetate incorporation into triglycerides, which may indicate an improvement in the action of insulin. Antidiabetic

New asymmetric synthesis of enantiomeric pairs of the 2-substituted pyrrolidines bgugaine and irniine

A new asymmetric route to 2-substituted pyrrolidines starting with the Sharpless asymmetric dihydroxylation (AD) of 4-pentenylphthalimide (5) followed by aminocyclization of the resultant amino alcohol is presented. The application to the asymmetric synth

LEUKOTRIENE ANTAGONISTS

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, processes for the preparation thereof, and pharmaceutical compositions containing such compounds.This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.